Medicare Part D

  1. Industry payments were linked to more brand-name MS prescribing
    Pharmaceutical payments to clinicians correlated with reduced generic prescribing for MS medications, increasing costs for patients and the healthcare system overall.
  2. Most favored nation drug pricing may lower industry research revenue
    Analysis of most favored nation drug pricing as policy mechanism to reduce international price disparities and effects on pharmaceutical research investment and innovation.